RiverPark Advisors released their Q2 2025 investor letter, showcasing a 15.01% return for their Large Growth Fund. Strong performance was driven by sectors like technology and communication services. Eli Lilly and Company saw a decline despite growth in sales, with shares down 5.24% over the last 52 weeks.

RiverPark Large Growth Fund reported that Eli Lilly and Company faced challenges in Q2 2025, missing earnings expectations and dealing with pricing dynamics. Despite strong top-line growth, EPS fell below consensus due to lower pricing and supply disruptions. Eli Lilly and Company is ranked 21st among hedge funds’ most popular stocks.

In Q2 2025, 119 hedge fund portfolios held Eli Lilly and Company, up from 115 in the previous quarter. The company reported a 45% increase in revenue compared to Q1 2024. While Eli Lilly shows potential, some AI stocks may offer greater upside. Investors can explore more investor letters from leading investors for insights.

For more details on Eli Lilly and Company and other investment opportunities, check out additional articles on Insider Monkey. The company’s stock performance and potential are discussed in-depth, providing valuable insights for investors. No promotions or marketing of services are included in the article.

Read more at Yahoo Finance: Eli Lilly and Company (LLY) Slid Despite Strong Top-Line Growth